Froeding LP, Høgdall C, Kristensen E, et al. - Among sentinel node (SN)- negative vulva cancer (VC) patients, researchers assessed the risk of recurrence and survival. They gathered and prospectively registered nationwide data in the Danish Gynecologic Cancer Database from January 2011 to July 2017. Participants were patients having clinically stage IB-II unifocal vulva squamous cell carcinoma, tumor < 4 cm and no clinically doubtful groin nodes or distant metastases, who experienced SN-procedure. A total of 286 patients underwent SN-procedure, of these, SN-negative were 190 (66.4%) patients. During a median observation period of 30 months (range 1–83), the occurrence of one or more recurrences was reported in 23 of the 190 SN-negative patients (12.1%). For SN-negative patients, the 3-year overall (OS) was estimated to be 84% and disease-specific survival (DSS) was identified to be 93%. For those with recurrent disease, the estimated 3-year OS was 58%. In this largest prospective nationwide investigation on SN-procedure in vulva cancer, findings corroborated that the SN-procedure is safe in selected early-stage VC patients with a low isolated groin recurrence rate and a good DSS.